Z6尊龙
Other Affiliated Sites
Techdow Pharma China
Techdow Pharma UK
Techdow Pharma Poland
Techdow Pharma Italy
Techdow Pharma Spain
Techdow Pharma Germany
Techdow Pharma US
Cytovance Biologics
SPL
Simplified Chinese
Traditional Chinese
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
Global Industrial Chain
Global Heparin Injections Business
Product Profile
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Job Opportunities
Campus Recruitment
Contact Us
Create Value for Investors Through
Safe and Stable Operations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Disclosures
A-Share Information
H-Share Information
Financial Reports
Announcements
2020.01.23
2019年度业绩预告
2020.01.15
关于向银行申请综合授信额度的通告
2020.01.15
第四届董事会第二十八次聚会决议通告
2019.12.28
关于首次果真刊行境外上市外资股(H股)申请质料获中国证监会受理的通告
2019.12.21
关于控股股东股权质押的通告
2019.12.19
2019年第四次暂时股东大会的执法意见书
2019.12.19
2019年第四次暂时股东大会决议通告
2019.12.14
关于股东股权扫除质押的通告
2019.12.07
第四届董事会第二十七次聚会决议通告
2019.12.07
关于延伸公司第二期员工持股妄想存续期的通告
第一页
上一页
36
37
38
39
40
下一页
最后一页
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Job Opportunities
Campus Recruitment
Contact Us
Official WeChat Account
Legal Statement
·
Environmental Disclosure
Copyright ? 2024 Hepalink Group. All Rights Reserved.
【网站地图】
【sitemap】